Annexin A8 is a novel molecular marker for detecting lymph node metastasis in oral squamous cell carcinoma
Metrics: PDF 1285 views | HTML 1469 views | ?
Ryota Oka1,*, Koh-ichi Nakashiro1,*, Hiroyuki Goda1, Kazuki Iwamoto1, Norihiko Tokuzen1, Hiroyuki Hamakawa1
1Department of Oral and Maxillofacial Surgery, Ehime University Graduate School of Medicine, Toon, Ehime 791-0295, Japan
*These authors have contributed equally to this work
Koh-ichi Nakashiro, e-mail: email@example.com
Keywords: oral squamous cell carcinoma (OSCC), lymph node metastasis, keratin 19 (KRT19), annexin A8 (ANXA8), reverse transcription loop-mediated isothermal amplification (RT-LAMP)
Received: August 04, 2015 Accepted: December 05, 2015 Published: December 17, 2015
Cervical lymph node metastasis is an important prognostic factor in oral squamous cell carcinoma (OSCC), but its accurate assessment after sentinel node biopsy or neck dissection is often limited to the histopathological examination of only one or two sections. Previous our study showed the usefulness of the reverse transcription loop-mediated isothermal amplification (RT-LAMP) targeting keratin 19 (KRT19) mRNA for the genetic detection of lymph node metastasis, but the sensitivity was insufficient. Here, we have attempted to identify novel molecular markers for OSCC cells in lymph nodes. We performed microarray analysis to identify genes overexpressed in 7 metastatic lymph nodes from OSCC patients, compared to 1 normal lymph node and 5 salivary glands from non-cancer patients. We then used real-time quantitative RT-PCR (qRT-PCR) and RT-LAMP to compare the expression of these genes in newly resected metastatic and normal lymph nodes. Of 4 genes identified by microarray analysis, annexin A8 (ANXA8) and desmoglein 3 mRNA were detected by qRT-PCR in metastatic lymph nodes but not in normal lymph nodes. Furthermore, ANXA8 mRNA expression was detected in all KRT19-negative metastatic lymph nodes. Both KRT19 and ANXA8 mRNA may be useful markers for detecting lymph node metastases in OSCC patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.